Contrast-enhanced sonography-guided radiofrequency ablation for the local recurrence of previously treated hepatocellular carcinoma undetected by b-mode sonography

Journal of Clinical Ultrasound

Volumn 38, Issue 7, 2010, Pages 339-345

  Miyamoto, Noriyuki ^a   Hiramatsu, Kazuhide ^a   Tsuchiya, Kazuhiko ^a   Sato, Yukihiko ^a  

^a Obihiro Kosei Hospital   (Japan)

Author keywords

Contrast agent; Hepatocellular carcinoma; Radiofrequency ablation; Sonazoid; Ultrasonography

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; FERRIC ION; IRON; NYCOMED; OXIDE;

AGED; ARTICLE; CATHETER ABLATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMAGE ENHANCEMENT; IMAGE PROCESSING; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CONTRAST MEDIA; FEMALE; FERRIC COMPOUNDS; FOLLOW-UP STUDIES; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXIDES; TREATMENT OUTCOME;

EID: 77956608789     PISSN: 00912751     EISSN: 10970096     Source Type: Journal    
DOI: 10.1002/jcu.20720     Document Type: Article

References (39)

1. Colombo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1981;325:675.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907.
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519.
4. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous imageguided radiofrequency ablation. Radiology 2005; 234:961.
5. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: A unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol 2000;174:323.
6. Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000;232:381.
7. Horiike N, Iuchi H, Ninomiya T, et al. Influencing factors for recurrence of hepatocellular carcinoma treated with radiofrequency ablation. Oncol Rep 2002;9:1059.
8. Hori T, Nagata K, Hasuike S, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol 2003;38:977.
9. Komorizono Y, Oketani M, Sako K, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 2003;97:1253.
10. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235.
11. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122.
12. Harrison LE, Koneru B, Baramipour P, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surge 2003;197:759.
13. Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology 1999;210:655.
14. Ikeda M, Okuda S, Ueno H, et al. Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: A comparative study. Jpn J Clin Oncol 2001;31:322.
15. Numata K, Tanaka K, Kiba T, et al. Nonresectable hepatocellular carcinoma: Improved percutaneous ethanol injection therapy guided by CO(2)- enhanced sonography. AJR Am J Roentgenol 2001; 177:789.
16. Numata K, Tanaka K, Kiba T, et al. Using contrast- enhanced sonography to assess the effectiveness of transcatheter arterial embolization for hepatocellular carcinoma. AJR Am J Roentgenol 2001;176:1199.
17. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008;75(Suppl 1):1.
18. Chopra S, Dodd GD 3rd, Chintapalli KN, et al. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. AJR Am J Roentgenol 2001;177:381.
19. Ebara M, Kita K, Sugiura N, et al. Therapeutic effect of percutaneous ethanol injection on small hepatocellular carcinoma: evaluation with CT. Radiology 1995;195:371.
20. Catalano O, Lobianco R, Esposito M, et al. Hepatocellular carcinoma recurrence after percutaneous ablation therapy: helical CT patterns. Abdom Imaging 2001;26:375.
21. Okuda K. Hepatocellular carcinoma. J Hepatol 2000;32:225.
22. Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007;188:480.
23. Cioni D, Lencioni R, Rossi S, et al. Radiofrequency thermal ablation of hepatocellular carcinoma: Using contrast-enhanced harmonic power Doppler sonography to assess treatment outcome. AJR Am J Roentgenol 2001;177:789.
24. Sato M, Watanabe Y, Tokui K, et al. CT-guided treatment of ultrasonically invisible hepatocellular carcinoma. Am J Gastroenterol 2000;95:2102.
25. Miyamoto N, Hiramatsu K, Tsuchiya K, et al. Carbon dioxide microbubbles-enhanced sonographically guided radiofrequency ablation: treatment of patients with local progression of hepatocellular carcinoma. Radiat Med 2008;26:92.
26. Hirooka M, Iuchi H, Kumagi T, et al. Virtual sonographic radiofrequency ablation of hepatocellular carcinoma visualized on CT but not on conventional sonography. AJR Am J Roentgenol 2006; 186:S255.
27. Kudo K, Moriyasu F, Mine Y, et al. Preoperative RFA simulation for liver cancer using a CT virtual ultrasound system. Eur J Radiol 2007;61:324.
28. Maruyama H, Kobayashi S, Yoshizumi H, et al. Application of percutaneous ultrasound-guided treatment for ultrasonically invisible hypervascular hepatocellular carcinoma using microbubble contrast agent. Clin Radiol 2007;62:668.
29. Sontum PC, Ostensen J, Dyrstad K, et al. Acoustic properties of NC100100 and their relation with the microbubble size distribution. Invest Radiol 1999; 34:268.
30. Marelli C. Preliminary experience with NC100 100, a new ultrasound contrast agent for intravenous injection. Eur Radiol 1999;9(Suppl 3):343.
31. Hatanaka K, Kudo M, Minami Y, et al. Differential diagnosis of hepatic tumors: value of contrastenhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008;51:61.
32. Tanaka M, Nakashima O, Wada Y, et al. Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology 1996;24:807.
33. Xia Y, Kudo M, Minami Y, et al. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography. Oncology 2008;75(Suppl 1):99.
34. Nakano H, Ishida Y, Hatakeyama T, et al. Contrast- enhanced intraoperative ultrasonography equipped with late Kupffer-phase image obtained by sonazoid in patients with colorectal liver metastases. World J Gastroenterol 2008;14:3207.
35. Kudo M, Hatanaka K, Chung H, et al. A proposal of novel treatment-assist technique for hepatocellular carcinoma in the Sonazoid-enhanced ultrasonography: Value of defect re-perfusion imaging. Kanzo 2007;48:299.
36. Miyamoto N, Hiramatsu K, Tsuchiya K, et al. Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: Better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. Jpn J Radiol 2009;27:185.
37. Kei SK, Rhim H, Choi D, et al. Local tumor progression after radiofrequency ablation of liver tumors: Analysis of morphologic pattern and site of recurrence. AJR Am J Roentgenol 2008;190:1544.
38. Kim YS, Rhim H, Cho OK, et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: Analysis of the pattern and risk factors. Eur J Radiol 2006;59:432.
39. Bruix J, Sherman M, Llovet JM, et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma Conclusions of the Barcelona- 2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 2001;35: 421.